PKO Investment Management Joint Stock Co Sells 15,060 Shares of Abbott Laboratories $ABT

Key Points

• PKO Investment Management sold 15,060 shares of Abbott, reducing its stake by 38.6% to 24,000 shares worth about $3.01 million.
• Other institutions increased positions—most notably the Canada Pension Plan Investment Board added 292,547 shares and now holds 1,435,683 shares—and institutional investors collectively own 75.18% of ABT.
• Analysts have trimmed price targets but the consensus remains a Moderate Buy with an average target of $119.43; Abbott slightly beat Q1 estimates, gave FY‑2026 EPS guidance of 5.38–5.58, and announced a quarterly dividend of $0.63 (~2.8% yield).

PKO Investment Management Joint Stock Co lessened its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 38.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,000 shares of the healthcare product maker's stock after selling 15,060 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in Abbott Laboratories were worth $3,007,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC grew its position in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after purchasing an additional 162 shares in the last quarter. United Bank grew its position in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after purchasing an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC increased its stake in Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after buying an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after buying an additional 292,547 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ABT shares. Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Bank of America cut their price objective on Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Benchmark reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Finally, TD Cowen lowered their target price on Abbott Laboratories from $137.00 to $115.00 and set a "buy" rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $119.43.

Insiders Place Their Bets

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the business's stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 22,200 shares of company stock worth $2,215,100 and sold 3,055 shares worth $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Down 1.4%

NYSE:ABT opened at $89.51 on Friday. Abbott Laboratories has a 12 month low of $89.14 and a 12 month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.18 and a debt-to-equity ratio of 0.56. The firm's 50 day moving average is $104.33 and its 200 day moving average is $116.09. The stock has a market capitalization of $155.90 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 1.49 and a beta of 0.66.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period in the prior year, the company earned $1.09 earnings per share. Abbott Laboratories's revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.